Results 261 to 270 of about 1,795,367 (304)

Immunotherapy of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, 2001
Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel, M R, Baer, D E, Hogge, R K, Stuart   +3 more
openaire   +2 more sources

Transplantation in Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2014
Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire   +2 more sources

Cytogenetics in acute myeloid leukemia

Current Oncology Reports, 2002
Cytogenetic analysis is the most important diagnostic tool for determining prognosis in acute myeloid leukemia (AML). In the majority of patients with AML, acquired clonal chromosome aberrations can be observed. Numerous recurrent karyotype abnormalities have been discovered in AML.
Claudia, Schoch, Torsten, Haferlach
openaire   +2 more sources

Pharmacogenomics in Acute Myeloid Leukemia

Pharmacogenomics, 2009
Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe, Roumier, Meyling H, Cheok
openaire   +2 more sources

Metabolomics in acute myeloid leukemia

Molecular Genetics and Metabolism, 2020
Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML.
Anna V, Wojcicki, Maya M, Kasowski, Kathleen M, Sakamoto, Norman, Lacayo   +3 more
openaire   +2 more sources

Adult Acute Myeloid Leukemia

Mayo Clinic Proceedings, 2006
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour, Elihu, Estey, Hagop M, Kantarjian   +2 more
openaire   +2 more sources

Decitabine in Acute Myeloid Leukemia

Seminars in Hematology, 2005
Standard induction chemotherapy, depending on patient tolerability, is at present the treatment of choice in patients with acute myeloid leukaemia (AML) under the age of 75 years. Since AML is a disease primarily of the elderly, a large proportion of patients do not receive this therapy; therefore, novel treatment modalities are warranted. In addition,
Lübbert, Michael, Minden, Mark
openaire   +3 more sources

Angiogenesis in acute myeloid leukemia

Blood, 2000
We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO, G. A. PALUMBO, M. P. AZZARO, R. GIUSTOLISI   +3 more
openaire   +3 more sources

Acute Myeloid Leukemia in the Elderly

Seminars in Oncology, 2008
The incidence of acute myeloid leukemia (AML) is increasing with age. As the results associated with standard intensive chemotherapy remain particularly disappointing in older patients, they represent an ideal target population for clinical and therapeutic investigations.
Hervé, Dombret, Emmanuel, Raffoux, Claude, Gardin   +2 more
openaire   +2 more sources

Immunotherapy in Acute Myeloid Leukemia

Immunotherapy, 2013
Treatment of acute myeloid leukemia (AML) with current chemotherapy regimens is still disappointing, with overall survival rates of ≤ 40% at 5 years. It is now well established that AML cells can evade the immune system through multiple mechanisms, including the expression of the enzyme indoleamine 2,3 dioxygenase.
Mario, Arpinati, Antonio, Curti
openaire   +2 more sources